Does OFATUMUMAB Cause Second primary malignancy? 33 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 33 reports of Second primary malignancy have been filed in association with OFATUMUMAB (ARZERRA). This represents 0.1% of all adverse event reports for OFATUMUMAB.
33
Reports of Second primary malignancy with OFATUMUMAB
0.1%
of all OFATUMUMAB reports
9
Deaths
9
Hospitalizations
How Dangerous Is Second primary malignancy From OFATUMUMAB?
Of the 33 reports, 9 (27.3%) resulted in death, 9 (27.3%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OFATUMUMAB. However, 33 reports have been filed with the FAERS database.
What Other Side Effects Does OFATUMUMAB Cause?
Fatigue (5,202)
Headache (4,430)
Pain (3,382)
Chills (3,372)
Pyrexia (3,370)
Influenza like illness (2,727)
Nausea (1,688)
Multiple sclerosis relapse (1,525)
Covid-19 (1,435)
Asthenia (1,393)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which OFATUMUMAB Alternatives Have Lower Second primary malignancy Risk?
OFATUMUMAB vs OFLOXACIN
OFATUMUMAB vs OLANZAPINE
OFATUMUMAB vs OLANZAPINE\SAMIDORPHAN L-MALATE
OFATUMUMAB vs OLAPARIB
OFATUMUMAB vs OLARATUMAB